You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

488 Results
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
Exceptional Access Program
    olaparib - In combination with abiraterone, and prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abiraterone,
olaparib,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-2
Nov 2024
Document
Jan 2025
Document
Jan 2025
Document
Jan 2025
Document
Jan 2025
Statistical Reports
Les statistiques sur le cancer en Ontario 2024 représentent le cinquième d'une série de rapports qui fournissent des informations approfondies sur l'...
Dec 1969
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-3
Mar 2025
Drug
Other Name(s): Retevmo™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Document
Dec 1969
Drug
Other Name(s): Tecentriq® SC
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 1969
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
nivolumab (Unfunded),
DOXOrubicin,
vinBLAStine,
dacarbazine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph

Pages